Management and control strategies for community-associated methicillin-resistant Staphylococcus aureus

Edina Avdic, Sara Cosgrove

Research output: Contribution to journalArticle

Abstract

Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is now a common cause of skin and soft tissue infections and has been implicated in some cases of severe pneumonia and necrotising fasciitis in both children and adults. Objective: This review summarises the available evidence on the management and therapeutic options for the treatment of CA-MRSA, including antibiotic options for both mild and severe disease and prevention and decolonisation strategies. Methods: An extensive Medline literature search was performed to identify relevant articles and selected conference abstracts were incorporated. Results/conclusion: The optimal therapy for CA-MRSA infections has not been fully elucidated. Incision and drainage of purulent lesions and good follow-up wound care are important; adjuvant antibiotic therapy should be considered on the basis of location and extent of disease, systemic symptoms and host risk factors for complicated disease. Patients with severe disease (such as pneumonia and necrotising fasciitis) may require intensive care unit (ICU) care. CA-MRSA is usually susceptible to a variety of oral non-β-lactam antibiotics, such as trimethoprim/sulfamethoxazole, clindamycin. tetracyclines and linezolid. Parenteral therapy with vancomycin or daptomycin can also be considered.

Original languageEnglish (US)
Pages (from-to)1463-1479
Number of pages17
JournalExpert Opinion on Pharmacotherapy
Volume9
Issue number9
DOIs
StatePublished - Jun 2008

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Necrotizing Fasciitis
Linezolid
Anti-Bacterial Agents
Pneumonia
Daptomycin
Therapeutics
Lactams
Tetracyclines
Aftercare
Soft Tissue Infections
Clindamycin
Sulfamethoxazole Drug Combination Trimethoprim
Vancomycin
Intensive Care Units
Drainage
Skin
Wounds and Injuries
Infection

Keywords

  • CA-MRSA
  • Clindamycin
  • Community-associated methicillin-resistant Staphylococcus aureus
  • Community-associated MRSA
  • Daptomycin
  • Doxycycline
  • Fluoroquinolones
  • Linezolid
  • Minocycline
  • MRSA
  • Panton-Valentine leucocidin
  • Rifampin
  • Tetracyclines
  • Tigecycline
  • Trimethoprim/sulfamethoxazole
  • Vancomycin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Management and control strategies for community-associated methicillin-resistant Staphylococcus aureus. / Avdic, Edina; Cosgrove, Sara.

In: Expert Opinion on Pharmacotherapy, Vol. 9, No. 9, 06.2008, p. 1463-1479.

Research output: Contribution to journalArticle

@article{f6d78428b17f4189a0abbc125cd2d350,
title = "Management and control strategies for community-associated methicillin-resistant Staphylococcus aureus",
abstract = "Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is now a common cause of skin and soft tissue infections and has been implicated in some cases of severe pneumonia and necrotising fasciitis in both children and adults. Objective: This review summarises the available evidence on the management and therapeutic options for the treatment of CA-MRSA, including antibiotic options for both mild and severe disease and prevention and decolonisation strategies. Methods: An extensive Medline literature search was performed to identify relevant articles and selected conference abstracts were incorporated. Results/conclusion: The optimal therapy for CA-MRSA infections has not been fully elucidated. Incision and drainage of purulent lesions and good follow-up wound care are important; adjuvant antibiotic therapy should be considered on the basis of location and extent of disease, systemic symptoms and host risk factors for complicated disease. Patients with severe disease (such as pneumonia and necrotising fasciitis) may require intensive care unit (ICU) care. CA-MRSA is usually susceptible to a variety of oral non-β-lactam antibiotics, such as trimethoprim/sulfamethoxazole, clindamycin. tetracyclines and linezolid. Parenteral therapy with vancomycin or daptomycin can also be considered.",
keywords = "CA-MRSA, Clindamycin, Community-associated methicillin-resistant Staphylococcus aureus, Community-associated MRSA, Daptomycin, Doxycycline, Fluoroquinolones, Linezolid, Minocycline, MRSA, Panton-Valentine leucocidin, Rifampin, Tetracyclines, Tigecycline, Trimethoprim/sulfamethoxazole, Vancomycin",
author = "Edina Avdic and Sara Cosgrove",
year = "2008",
month = "6",
doi = "10.1517/14656566.9.9.1463",
language = "English (US)",
volume = "9",
pages = "1463--1479",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Management and control strategies for community-associated methicillin-resistant Staphylococcus aureus

AU - Avdic, Edina

AU - Cosgrove, Sara

PY - 2008/6

Y1 - 2008/6

N2 - Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is now a common cause of skin and soft tissue infections and has been implicated in some cases of severe pneumonia and necrotising fasciitis in both children and adults. Objective: This review summarises the available evidence on the management and therapeutic options for the treatment of CA-MRSA, including antibiotic options for both mild and severe disease and prevention and decolonisation strategies. Methods: An extensive Medline literature search was performed to identify relevant articles and selected conference abstracts were incorporated. Results/conclusion: The optimal therapy for CA-MRSA infections has not been fully elucidated. Incision and drainage of purulent lesions and good follow-up wound care are important; adjuvant antibiotic therapy should be considered on the basis of location and extent of disease, systemic symptoms and host risk factors for complicated disease. Patients with severe disease (such as pneumonia and necrotising fasciitis) may require intensive care unit (ICU) care. CA-MRSA is usually susceptible to a variety of oral non-β-lactam antibiotics, such as trimethoprim/sulfamethoxazole, clindamycin. tetracyclines and linezolid. Parenteral therapy with vancomycin or daptomycin can also be considered.

AB - Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is now a common cause of skin and soft tissue infections and has been implicated in some cases of severe pneumonia and necrotising fasciitis in both children and adults. Objective: This review summarises the available evidence on the management and therapeutic options for the treatment of CA-MRSA, including antibiotic options for both mild and severe disease and prevention and decolonisation strategies. Methods: An extensive Medline literature search was performed to identify relevant articles and selected conference abstracts were incorporated. Results/conclusion: The optimal therapy for CA-MRSA infections has not been fully elucidated. Incision and drainage of purulent lesions and good follow-up wound care are important; adjuvant antibiotic therapy should be considered on the basis of location and extent of disease, systemic symptoms and host risk factors for complicated disease. Patients with severe disease (such as pneumonia and necrotising fasciitis) may require intensive care unit (ICU) care. CA-MRSA is usually susceptible to a variety of oral non-β-lactam antibiotics, such as trimethoprim/sulfamethoxazole, clindamycin. tetracyclines and linezolid. Parenteral therapy with vancomycin or daptomycin can also be considered.

KW - CA-MRSA

KW - Clindamycin

KW - Community-associated methicillin-resistant Staphylococcus aureus

KW - Community-associated MRSA

KW - Daptomycin

KW - Doxycycline

KW - Fluoroquinolones

KW - Linezolid

KW - Minocycline

KW - MRSA

KW - Panton-Valentine leucocidin

KW - Rifampin

KW - Tetracyclines

KW - Tigecycline

KW - Trimethoprim/sulfamethoxazole

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=46749150620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749150620&partnerID=8YFLogxK

U2 - 10.1517/14656566.9.9.1463

DO - 10.1517/14656566.9.9.1463

M3 - Article

C2 - 18518778

AN - SCOPUS:46749150620

VL - 9

SP - 1463

EP - 1479

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 9

ER -